ARAX Capital Partners

Founded in 2012 and headquartered in Vienna, Austria, EveliQure Biotechnologies develops vaccines for preventing diarrheal diseases. Its flagship product is a combined vaccine designed to protect against both Shigella and ETEC bacteria, marking the first time such broad protection has been achieved.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

CONDA Crowdinvesting Österreich is an equity crowdfunding platform based in Vienna, Austria, that facilitates corporate investments and financing for startups and small businesses. The platform enables entrepreneurs to raise capital online, providing them with access to a diverse pool of investors. By focusing on various market segments, CONDA allows investors to make scalable and feasible investments, thereby supporting the growth and development of emerging companies. This model not only benefits businesses seeking funding but also empowers individual investors to participate in the financing of innovative ventures.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

Panoptes Pharma is a privately held biotechnology company based in Vienna, Austria, specializing in the development of small molecule therapies for severe eye diseases with significant unmet medical needs. The company's lead clinical candidate, PP-001, targets autoimmune uveitis, a major cause of blindness, and also aims to address adenoviral conjunctivitis, for which there is currently no available treatment. With its unique mode of action, PP-001 has the potential to be effective for various other inflammatory and viral conditions. Panoptes is supported by a team of experienced development experts who have a successful history in bringing innovative products to market, focusing on a targeted portfolio of high-performance small molecule treatments to enhance patient care in ophthalmology.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

CONDA Crowdinvesting Österreich is an equity crowdfunding platform based in Vienna, Austria, that facilitates corporate investments and financing for startups and small businesses. The platform enables entrepreneurs to raise capital online, providing them with access to a diverse pool of investors. By focusing on various market segments, CONDA allows investors to make scalable and feasible investments, thereby supporting the growth and development of emerging companies. This model not only benefits businesses seeking funding but also empowers individual investors to participate in the financing of innovative ventures.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

Marinomed Biotech AG is a biopharmaceutical company based in Vienna, Austria, specializing in the development of innovative therapies for respiratory and ophthalmological diseases. Founded in 2006, the company operates primarily through two technology platforms: Marinosolv and Carragelose. Marinosolv enables the creation of stable aqueous formulations for poorly soluble compounds, enhancing their bioavailability and therapeutic efficacy, while Carragelose offers antiviral solutions aimed at respiratory viruses. Marinomed's product portfolio includes nasal sprays, throat sprays, and lozenges designed to block viruses and alleviate symptoms associated with conditions such as cough, cold, influenza, and allergic rhinitis. The company collaborates with partners to market its products globally, focusing on improving treatment options for patients with sensitive tissues in the nose and eyes.

Founded in 2007, EUCODIS Bioscience specializes in the development and manufacturing of enzyme solutions for diverse industries such as biopharma, fine chemicals, cosmetics, food, feed, and more. Its portfolio includes lipases, peroxidases, phospholipase D, nitril hydratases, and other enzymes, catering to applications like chiral resolution, ester synthesis, fat production, hydrolysis/esterification, emollient ester synthesis, and bioplastic modification refinement.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Marinomed Biotech AG is a biopharmaceutical company based in Vienna, Austria, specializing in the development of innovative therapies for respiratory and ophthalmological diseases. Founded in 2006, the company operates primarily through two technology platforms: Marinosolv and Carragelose. Marinosolv enables the creation of stable aqueous formulations for poorly soluble compounds, enhancing their bioavailability and therapeutic efficacy, while Carragelose offers antiviral solutions aimed at respiratory viruses. Marinomed's product portfolio includes nasal sprays, throat sprays, and lozenges designed to block viruses and alleviate symptoms associated with conditions such as cough, cold, influenza, and allergic rhinitis. The company collaborates with partners to market its products globally, focusing on improving treatment options for patients with sensitive tissues in the nose and eyes.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Marinomed Biotech AG is a biopharmaceutical company based in Vienna, Austria, specializing in the development of innovative therapies for respiratory and ophthalmological diseases. Founded in 2006, the company operates primarily through two technology platforms: Marinosolv and Carragelose. Marinosolv enables the creation of stable aqueous formulations for poorly soluble compounds, enhancing their bioavailability and therapeutic efficacy, while Carragelose offers antiviral solutions aimed at respiratory viruses. Marinomed's product portfolio includes nasal sprays, throat sprays, and lozenges designed to block viruses and alleviate symptoms associated with conditions such as cough, cold, influenza, and allergic rhinitis. The company collaborates with partners to market its products globally, focusing on improving treatment options for patients with sensitive tissues in the nose and eyes.

Crystalsol is a technology company specializing in the development and manufacturing of innovative photovoltaic modules, primarily focused on building integration applications and consumer products. Founded in 2007 and based in Tallinn, Estonia, with additional operations in Vienna, Austria, Crystalsol utilizes a patented technology that combines high-efficiency single-crystalline materials with cost-effective roll-to-roll production methods. The company’s modules feature a light-absorbing layer made from a unique crystalline semiconductor powder, which consists of abundant and low-cost elements such as copper, zinc, tin, sulfur, and selenium. This technology allows for the creation of flexible photovoltaic films that can be seamlessly integrated into various structures, including building windows, facades, and rooftops. By eliminating the need for vacuum technology and enabling high throughput, Crystalsol's production process minimizes the capital investment typically required for photovoltaic plants, thereby addressing common scalability challenges associated with thin film technologies.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

Founded in 2007, EUCODIS Bioscience specializes in the development and manufacturing of enzyme solutions for diverse industries such as biopharma, fine chemicals, cosmetics, food, feed, and more. Its portfolio includes lipases, peroxidases, phospholipase D, nitril hydratases, and other enzymes, catering to applications like chiral resolution, ester synthesis, fat production, hydrolysis/esterification, emollient ester synthesis, and bioplastic modification refinement.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.